---
title: "CUMBERLAND PHARMACEUTICALS INC 2026: Revenue $166.46K, EPS ($0.29) — 10-Q Summary"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295280060.md"
description: "Cumberland Pharmaceuticals reported Q1 2026 results with revenue of $166.46K, down 56.3% YoY, and a net loss of $4.28M. The decline reflects the strategic sale of its branded portfolio to Apotex for ~$100 million, shifting focus to development-stage programs. Proceeds funded a special dividend and pipeline investments. Key highlights include positive Phase 2 data for Ifetroban in Duchenne muscular dystrophy and oncology metastasis prevention."
datetime: "2026-08-07T21:21:04.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295280060.md)
  - [en](https://longbridge.com/en/news/295280060.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295280060.md)
generator: "portal-rs"
---

# CUMBERLAND PHARMACEUTICALS INC 2026: Revenue $166.46K, EPS ($0.29) — 10-Q Summary

Cumberland Pharmaceuticals Inc reported first-quarter 2026 results showing sharply lower revenue and a wider net loss versus the prior-year quarter, reflecting the company's transition after the sale of its branded portfolio and ongoing investment in development-stage programs.

**Financial Highlights**

Metric

Current quarter

Prior year quarter

YoY change

Revenue¹

$166.46K

$380.8K

(56.3%)

Net income²

($4.28M)

($740.74K)

(477.3%)

Diluted EPS³

($0.29)

($0.05)

(480%)

*¹ Reported as “Net revenues from continuing operations”. ² Reported as “Net income (loss) attributable to common shareholders”. ³ Reported as “Income (loss) per share attributable to common shareholders”.*

**Business Highlights**

-   Completed strategic sale of its branded FDA-approved portfolio to Apotex, repositioning the company to focus on pipeline and development-stage operations.
-   Ifetroban advanced across multiple Phase 2 programs — notably breakthrough results in Duchenne muscular dystrophy (DMD) with ongoing enrollment in DMD, systemic sclerosis (SSc) and idiopathic pulmonary fibrosis (IPF) studies.
-   Positive safety and trend findings were reported in a Phase 2 oncology metastasis prevention study, indicating potential reduced recurrence.
-   Received approximately $100 million in proceeds from the portfolio sale, enabling a special dividend, funding of development programs, and support for CET incubation activities.

Original SEC Filing: CUMBERLAND PHARMACEUTICALS INC \[ CPIX \] - 10-Q - Aug. 07, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [CPIX.US](https://longbridge.com/en/quote/CPIX.US.md)

## Related News & Research

- [17:06 ETCUMBERLAND PHARMACEUTICALS REPORTS COMPANY UPDATE & Q2 2026 FINANCIAL RESULTS](https://longbridge.com/en/news/294873099.md)
- [Cumberland Pharmaceuticals Q2 FY26 net loss widens to USD 4.1 million; revenue falls 56.28% to USD 166,458](https://longbridge.com/en/news/294877259.md)
- [Capricor says FDA sets Nov. 22 PDUFA date for deramiocel in Duchenne muscular dystrophy](https://longbridge.com/en/news/296796555.md)
- [MSCL: SAT-3247 shows early clinical promise for DMD, with strong safety, efficacy, and financial backing](https://longbridge.com/en/news/296385164.md)
- [Satellos Bioscience posts investor deck outlining SAT-3247 muscle-regeneration approach for Duchenne dystrophy](https://longbridge.com/en/news/296435378.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**